Peptide Initiative

Peptides · Peptide comparison

Defensin (HBD-3) vs Thymosin Alpha-1

Most potent human beta-defensin (45 amino acids) with unique salt-insensitive antimicrobial activity — kills MRSA at MIC 0.5-1.0 μg/mL regardless of salt concentration, disrupts biofilms at 4-8 μg/mL, and retains full bactericidal function even without its disulfide bonds — representing a next-generation antimicrobial peptide template for combating antibiotic resistance

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeDefensin (HBD-3)200–200 mcg/mLThymosin Alpha-11.6–1.6 mg
FrequencyDefensin (HBD-3)As neededThymosin Alpha-1Twice weekly
AdministrationDefensin (HBD-3)Topical application (research/wound care)Thymosin Alpha-1Subcutaneous injection
Cycle lengthDefensin (HBD-3)Ongoing/indefiniteThymosin Alpha-18-12 weeks
Onset speedDefensin (HBD-3)Rapid (hours to days)Thymosin Alpha-1Moderate (1-2 weeks)
Evidence levelDefensin (HBD-3)Moderate human trials (Phase 1-2)Thymosin Alpha-1Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Fighting Drug-Resistant Bacteria

Defensin (HBD-3)96%
Thymosin Alpha-1No recorded rating

Wound Healing

Defensin (HBD-3)88%
Thymosin Alpha-1No recorded rating

Immune System Support

Defensin (HBD-3)82%
Thymosin Alpha-1No recorded rating

Immune Activation

Defensin (HBD-3)No recorded rating
Thymosin Alpha-195%

Infection Fighting

Defensin (HBD-3)No recorded rating
Thymosin Alpha-192%

Immune Balance

Defensin (HBD-3)No recorded rating
Thymosin Alpha-188%

Technical data

Compound specifications

Defensin (HBD-3)

Molecular formula
Approximately C220H340N64O62S6 (45-amino acid peptide with 3 disulfide bonds)
Molecular weight
~5,155 Da (mature peptide)
Half-life
Short systemic half-life (minutes) typical of cationic peptides; disulfide-bonded form provides protease resistance at local tissue sites; linear form shows adequate stability for topical applications
Bioavailability
Topical application achieves high local concentrations; maintains activity in physiological salt environments (unique); linear form retains activity enabling simplified formulation; not intended for oral or systemic delivery
CAS number
Not assigned (endogenous human peptide; research-grade available from peptide suppliers)

Thymosin Alpha-1

Molecular formula
C129H215N33O55
Molecular weight
3108.32 g/mol
Half-life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS number
62304-98-7

Protocols

Dosing compared

Defensin (HBD-3)

Topical

  • 200 µg/mL applied to the wound, about 4 µg per dose (20 µL)Every 2 days in the study · Until wound healed (study setting)HBD-3 is a research-only peptide with no human dosing protocol. No published study gives a topical peptide dose: the infected-diabetic-wound study on this page delivered hBD-3 by gene transfer, not as an applied peptide [6], so this amount is unsourced. Human use has not been established.

Thymosin Alpha-1

Subcutaneous injection

  • 1.6 mgTwice weekly (3-4 days apart) · 6-12 monthsEstablished clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
  • 1.6 mg daily, then 1.6 mg twice weeklyDaily for an initial loading period, then twice weekly · 12+ weeksThe schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].

Applications

Best suited for

Defensin (HBD-3)

Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections
Defensin (HBD-3) is particularly well-suited for individuals focused on research into anti-mrsa therapeutics and alternatives to vancomycin for resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of antimicrobial wound dressings and medical device coatings
Defensin (HBD-3) is particularly well-suited for individuals focused on development of antimicrobial wound dressings and medical device coatings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-biofilm strategies for chronic wound infections and implant-associated infections
Defensin (HBD-3) is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and implant-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Applications requiring antimicrobial activity in physiological or high-salt environments
Defensin (HBD-3) is particularly well-suited for individuals focused on applications requiring antimicrobial activity in physiological or high-salt environments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Alpha-1

Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.

Safety profile

Side effects

Defensin (HBD-3)

Common

  • Local site irritation
  • Transient inflammatory response
  • Mild wound bed changes

Uncommon

  • Localized allergic reaction
  • Mild cytotoxicity at high concentrations

Serious

  • No serious adverse effects documented at therapeutic concentrations

Thymosin Alpha-1

Common

  • Injection site reactions

Uncommon

  • Mild fatigue
  • Flu-like symptoms
  • Mild fever
  • Lymph node awareness

Serious

  • Allergic reaction

Research status

Safety & evidence

Defensin (HBD-3)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Defensin HBD-3 is not FDA-approved and has no completed human clinical trials, existing only in research contexts with in vitro and animal study data. Animal toxicology studies demonstrate no major systemic toxicity at doses exceeding therapeutic levels, but human immunological responses to exogenously administered defensin peptides have not been characterized. Risks include potential immune activation, cross-reactivity with self-antigens (due to HBD-3 expression in healthy epithelial cells), development of anti-peptide antibodies, and possible tolerance development with repeated dosing. Bacterial and fungal resistance to defensin-based therapy is theoretically possible. No human pharmacokinetics, dose-ranging studies, Phase 1 safety assessments, or clinical efficacy data exist.

Contraindications

  • Known hypersensitivity to defensin peptides or formulation components
  • Pregnancy and breastfeeding — insufficient safety data for exogenous defensin administration
  • Active autoimmune conditions — potential for immune activation through monocyte/macrophage recruitment
  • Severe hepatic or renal impairment — peptide clearance may be altered for any systemic exposure

Thymosin Alpha-1

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
Safety overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Contraindications

  • Organ transplant recipients on immunosuppressants
  • Active autoimmune disease flares
  • Known allergy to thymosin peptides
  • Pregnancy or breastfeeding
  • Children under 18 without medical supervision

Decision guide

Which is right for you?

Defensin (HBD-3)

Choose Defensin (HBD-3) if…

  • Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections
  • Development of antimicrobial wound dressings and medical device coatings
  • Anti-biofilm strategies for chronic wound infections and implant-associated infections
  • Applications requiring antimicrobial activity in physiological or high-salt environments

Thymosin Alpha-1

Choose Thymosin Alpha-1 if…

  • Immune system strengthening
  • Chronic infection support
  • Cancer adjunct therapy
  • Healthy aging immune support